Proteomics in Drug Development: The Dawn of a New Era?

被引:28
作者
Frantzi, Maria [1 ]
Latosinska, Agnieszka [1 ]
Mischak, Harald [1 ,2 ]
机构
[1] Mosaiques Diagnost GmbH, Rotenburger Str 20, D-30659 Hannover, Germany
[2] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland
关键词
drug discovery; mass spectrometry; proteomics; THERMAL SHIFT ASSAY; CELL LUNG-CANCER; MASS-SPECTROMETRY; TARGET DECONVOLUTION; THERAPEUTIC TARGET; PROTEIN; LIGAND; DISCOVERY; IDENTIFICATION; PROMOTES;
D O I
10.1002/prca.201800087
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Mass spectrometry offers the potential of acquiring high resolution data depicting the functional status of a group of healthy or diseased individuals, according to different conditions. As most of the drugs are currently targeting proteins, proteomics has a dual value, both in the discovery of new molecules as therapeutic targets, but also as a methodology to perform high throughput drug profiling. As there is an evident need for drugs to be improved in terms of efficacy, a mechanistic insight for downstream effectors can be valuable in order to predict side effects and resistance mechanisms. Recently developed assays, like thermal proteome profiling enables comprehensive drug target profiling and is, therefore, of high value in drug discovery. In this review, a systematic literature search is conducted and the most prominent proteomics studies as implicated in assisting drug discovery and development is presented. Focus is placed on investigations that are closer to implementation, therefore particular emphasis is given in studies conducted in human diseased population and further verified in vitro or in vivo.
引用
收藏
页数:13
相关论文
共 75 条
[1]   Mass spectrometry-based proteomics [J].
Aebersold, R ;
Mann, M .
NATURE, 2003, 422 (6928) :198-207
[2]   Identification of Nidogen 1 as a lung metastasis protein through secretome analysis [J].
Aleckovic, Masa ;
Wei, Yong ;
LeRoy, Gary ;
Sidoli, Simone ;
Liu, Daniel D. ;
Garcia, Benjamin A. ;
Kang, Yibin .
GENES & DEVELOPMENT, 2017, 31 (14) :1439-1455
[3]   Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion [J].
Armstrong, Heather K. ;
Gillis, Joanna L. ;
Johnson, Ian R. D. ;
Nassar, Zeyad D. ;
Moldovan, Max ;
Levrier, Claire ;
Sadowski, Martin C. ;
Chin, Mei Yieng ;
Guns, Emma S. Tomlinson ;
Tarulli, Gerard ;
Lynn, David J. ;
Brooks, Douglas A. ;
Selth, Luke A. ;
Centenera, Margaret M. ;
Butler, Lisa M. .
SCIENTIFIC REPORTS, 2018, 8
[4]   Identification of Novel Tumor-Associated Cell Surface Sialoglycoproteins in Human Glioblastoma Tumors Using Quantitative Proteomics [J].
Autelitano, Francois ;
Loyaux, Denis ;
Roudieres, Sebastien ;
Deon, Catherine ;
Guette, Frederique ;
Fabre, Philippe ;
Ping, Qinggong ;
Wang, Su ;
Auvergne, Romane ;
Badarinarayana, Vasudeo ;
Smith, Michael ;
Guillemot, Jean-Claude ;
Goldman, Steven A. ;
Natesan, Sridaran ;
Ferrara, Pascual ;
August, Paul .
PLOS ONE, 2014, 9 (10)
[5]   A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients [J].
Bai, Ya-hui ;
Zhan, Yun-bo ;
Yu, Bin ;
Wang, Wei-Wei ;
Wang, Li ;
Zhou, Jin-qiao ;
Chen, Ruo-kun ;
Zhang, Feng-jiang ;
Zhao, Xin-wei ;
Duan, Wen-chao ;
Wang, Yan-min ;
Liu, Jun ;
Bao, Jian-ji ;
Zhang, Zhen-yu ;
Liu, Xian-zhi .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 48 (04) :1755-1770
[6]   Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target [J].
Bassiri, Kayleigh ;
Ferluga, Sara ;
Sharma, Vikram ;
Syed, Nelofer ;
Adams, Claire L. ;
Lasonder, Edwin ;
Hanemann, C. Oliver .
EBIOMEDICINE, 2017, 16 :76-86
[7]   Chemoproteomics-enabled covalent ligand screen reveals a cysteine hotspot in reticulon 4 that impairs ER morphology and cancer pathogenicity [J].
Bateman, L. A. ;
Nguyen, T. B. ;
Roberts, A. M. ;
Miyamoto, D. K. ;
Ku, W. -M. ;
Huffman, T. R. ;
Petri, Y. ;
Heslin, M. J. ;
Contreras, C. M. ;
Skibola, C. F. ;
Olzmann, J. A. ;
Nomura, D. K. .
CHEMICAL COMMUNICATIONS, 2017, 53 (53) :7234-7237
[8]   Proteomics biomarkers for solid tumors: Current status and future prospects [J].
Belczacka, Iwona ;
Latosinska, Agnieszka ;
Metzger, Jochen ;
Marx, David ;
Vlahou, Antonia ;
Mischak, Harald ;
Frantzi, Maria .
MASS SPECTROMETRY REVIEWS, 2019, 38 (01) :49-78
[9]   Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia [J].
Bowen, Thomas Scott ;
Adams, Volker ;
Werner, Sarah ;
Fischer, Tina ;
Vinke, Paulien ;
Brogger, Maria Noel ;
Mangner, Norman ;
Linke, Axel ;
Sehr, Peter ;
Lewis, Joe ;
Labeit, Dittmar ;
Gasch, Alexander ;
Labeit, Siegfried .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2017, 8 (06) :939-953
[10]   CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity [J].
Burr, Marian L. ;
Sparbier, Christina E. ;
Chan, Yih-Chih ;
Williamson, James C. ;
Woods, Katherine ;
Beavis, Paul A. ;
Lam, Enid Y. N. ;
Henderson, Melissa A. ;
Bell, Charles C. ;
Stolzenburg, Sabine ;
Gilan, Omer ;
Bloor, Stuart ;
Noori, Tahereh ;
Morgens, David W. ;
Bassik, Michael C. ;
Neeson, Paul J. ;
Behren, Andreas ;
Darcy, Phillip K. ;
Dawson, Sarah-Jane ;
Voskoboinik, Ilia ;
Trapani, Joseph A. ;
Cebon, Jonathan ;
Lehner, Paul J. ;
Dawson, Mark A. .
NATURE, 2017, 549 (7670) :101-105